GlassScriptPhysician profile
Tulsi Sharma
NPI 1407180094
$2,991.39
in general payments reported to CMS, 2019-2025
26 companies · $200 in 2025
The $200 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,464 · 2020: $349 · 2021: $87.75 · 2022: $37.36 · 2023: $796 · 2024: $57.14 · 2025: $200.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $944 · Gift: $59.40 · Education: $50.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $944.26 |
| Gift | $59.40 |
| Education | $50.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $478.72 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $343.02 | 2019-2024 | Mounjaro, Jardiance, Humulin |
| Amgen INC. | $287.07 | 2019-2023 | Repatha |
| Abbott Laboratories | $241.93 | 2019-2024 | Freestyle Libre 2, Freestyle Libre 3 |
| Radius Health, INC. | $199.03 | 2019-2023 | |
| Mannkind Corporation | $172.85 | 2023 | Afrezza |
| Merck Sharp & Dohme LLC | $166.23 | 2019-2023 | Zerbaxa, Dificid, Recarbrio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.52 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $121.24 | 2019-2023 | Breztri |
| Sanofi-Aventis U.S. LLC | $121.12 | 2019 | |
| Neurocrine Biosciences, INC. | $102.81 | 2025 | |
| Dexcom, INC. | $97.53 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161) |
| Abbvie INC. | $68.99 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $64.08 | 2023 | Strensiq |
| Allergan, INC. | $59.29 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $50.42 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $49.18 | 2023 | |
| Shire North American Group INC | $41.26 | 2019 | |
| Insulet Corporation | $40.56 | 2019 | |
| Tandem Diabetes Care, INC. | $38.47 | 2023 | T:Slim X2 Insulin Pump With Control-Iq |
| Medtronic Minimed, INC. | $38.21 | 2019 | |
| Kyowa Kirin, INC. | $32.02 | 2023 | Crysvita |
| Daiichi Sankyo INC. | $14.38 | 2020 | |
| Xeris Pharmaceuticals, INC. | $12.65 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $12.14 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $11.67 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tulsi Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.